- Internal cGMP Audits
- GLP Audits
- GCP Audits
- Contract Manufacturer Audits
- Quality Systems Evaluation
- Compliance Gap Assessments
- Mock FDA Audits
- Compounding Pharmacy Audits
- Pre Approval Inspection Support
- API ICH Q7A Audits
- Labeling/Packaging Audits
- Supplier Audits
- Surveillance Audits
- Validation Audits
- Design of Audit Programs
- Dietary Supplement Compliance Audits
-
Contact GQA
- 1-303-459-2382
- 1-866-216-2815
- info@gqaconsulting.com
-
Industry Definitions
Compounding Pharmacy
USP<797> (Pharmaceutical Compounding - Sterile Preparations) became effective in 2004. 460.200 - Pharmacy Compounding Guidance was issued by FDA in 2002. The FDA has issued Warning Letters to pharmacy compounding facilities in violation of requirements outlined in <797> and 460.200, and FDA oversight of compounding facilities has increased. GQA can provide expertise in auditing to meet these requirements as well as design and develop procedures, systems, and facilities.
»More terms